A Phase 1, Single Ascending Dose Study to Evaluate the Safety of MEDI2338 in Subjects With Chronic Obstructive Pulmonary Disease.
Phase of Trial: Phase I
Latest Information Update: 22 Oct 2013
At a glance
- Drugs MEDI 2338 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- 11 May 2012 Actual patient number added 31 according to ClinicalTrials.gov.
- 11 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 04 Aug 2011 Planned End Date changed from 1 Feb 2012 to 1 Dec 2011 as reported by ClinicalTrials.gov.